Pembrolizumab (MK-3475) 是一种人源化 IgG4 抗体，为PD-1的抑制剂，用于癌症免疫的研究。
| 生物活性 | Pembrolizumab (MK-3475) is a humanizedIgG4antibody inhibiting the programmed cell death 1 (PD-1) receptor, used incancer immunotherapy. |
| IC50& Target | |
体外研究
(In Vitro) | Pembrolizumab (MK-3475) increases the secretion of cytokines IFN-γ, TNF-α and the apoptotic cell death of A549 cells[2].
Pembrolizumab improves the αROR1-CAR T-mediated cytotoxicity, and reduces tumorigenesis in the co-cultured αROR1-CAR T and A549 cells by blocking PD-1::PD-L1 interaction in αROR1-CAR T cells[2].
Cell Cytotoxicity Assay[2] | Cell Line: | αROR1-CAR T and A549 cells | | Concentration: | 10 μg/mL | | Incubation Time: | Adding Pembrolizumab after A549-Red-Fluc cells preconditioned in elevated pressure (+ 100 mmHg) for 7 days. | | Result: | Enhanced αROR1-CAR T killing of A549 lung cancer cells under elevated pressure. |
Apoptosis Analysis[2] | Cell Line: | A549 cells | | Concentration: | 10 μg/mL | | Incubation Time: | | | Result: | Increased the apoptotic cell death in A549 cells, and improve the αROR1-CAR T-mediated cytotoxicity. |
|
体内研究
(In Vivo) | Pembrolizumab inhibits tumor size in A549 xenograft mice pretreated by pressure[2].
| Animal Model: | Six-week-old male BALB/c athymic nude mice[2] | | Dosage: | 5 mg/kg | | Administration: | Pembrolizumab (5 mg/kg; Intravenous injection; Once) | | Result: | Reduced tumorigenesis in αROR1-CAR T cells and co-cultured with A549 cells. |
|
| Clinical Trial | |
| 分子量 | |
| 性状 | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
